2017 Health for Humanity Report
Our Approach
Our Approach
Our Approach
GRI
Global Reporting Initiative
102-10
Significant changes to the organization and its supply chain
102-46
Defining report content and topic Boundaries
102-48
Restatements of information
102-52
Reporting cycle
102-54
Claims of reporting in accordance with the GRI Standards
102-55
GRI content index
102-56
External assurance
Our Approach

About This Report

GRI
Global Reporting Initiative
102-10
Significant changes to the organization and its supply chain
102-46
Defining report content and topic Boundaries
102-48
Restatements of information
102-52
Reporting cycle
102-54
Claims of reporting in accordance with the GRI Standards
102-55
GRI content index
102-56
External assurance

Johnson & Johnson’s 2017 Health for Humanity Report is our 15th annual report on our progress in citizenship and sustainability. Data in this Report cover the period between January 1, 2017, and December 31, 2017, unless otherwise indicated. The Report is also available in a customizable PDF version. It includes an Executive Summary available in five languages.

This Report provides a comprehensive overview of the Company’s vision, strategic approach and performance in the environmental, social and governance areas relevant to our business. Reporting on other matters specific to financial performance of the Company and its subsidiaries can be found in our 2017 Annual Report.

The content of this Report covers Johnson & Johnson’s worldwide operations, including our subsidiaries across three business segments: Consumer, Medical Devices and Pharmaceutical. Contract manufacturers are excluded from the scope of this Report, unless otherwise noted. There have been no significant changes from our previous reporting period regarding scope, boundaries, or measurement methods applied. From an operational perspective, in June 2017, we completed the largest acquisition in our Company’s history, with Actelion becoming part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Pulmonary Hypertension is a new therapeutic area that was established within Janssen with the acquisition of Actelion. For more information, see the press release.

GRI Gold Logo

The Report has been prepared in accordance with the Global Reporting Initiative (GRI) Standards Core option. Please refer to the GRI Content Index for a complete listing of GRI disclosures included in this Report. Our 2016 Priority Topics Assessment process guided the Report’s structure.

The Report content is also informed by the UN Global Compact (UNGC) Principles and serves as our annual UNGC Communication on Progress. See the UNGC Index for more information on how we adhere to the 10 UNGC Principles.

This Report includes our annual update on progress against our Health for Humanity 2020 Goals and progress on our commitments to the UN Sustainable Development Goals (UN SDG). Please see Health for Humanity 2020 Goals Progress Scorecard and UN SDGs Progress Scorecard for more information.

All data in the Report have been subject to various forms of verification and assurance. ERM Certification and Verification Services (ERM/CVS) conducted independent review and assurance of the following information and data in the report:

  • Progress against our Health for Humanity 2020 Goals, and associated data presented in the 2020 Goals Progress Scorecard.
  • Progress against UN SDG commitments, and associated data presented in the UN SDG Scorecard.
  • Year 2017 global greenhouse gas (GHG) emissions inventory and electricity use generated from renewable energy sources that are also included in our 2018 CDP Climate Change Report.

Click here for ERM/CVS independent assurance statements. The financial data and general information about the business in this Report were previously audited for disclosure in our 2017 Annual Report.

We welcome stakeholder feedback on our Report. To share your comments or questions, please contact us at support@jnj.com.

BSR Reporting Commentary

BSR, a global nonprofit organization focused on corporate sustainability, has provided Johnson & Johnson with feedback on the content in the pre-publication drafts of the company's 2017 Health for Humanity Report. BSR's comments do not verify or otherwise provide an opinion on the accuracy or completeness of data or other information in the report. Instead, BSR's comments represent a perspective, based on our experience in the field of environmental and social reporting and on our work with Johnson & Johnson, on its reporting efforts to date and items we think worthy of improvement or addition in future years.

Strengths in Johnson & Johnson’s reporting include clear identification and organization around priority environmental, social, and governance issues, providing progress on Johnson & Johnson’s performance towards its Health for Humanity 2020 Goals, and describing how the company’s engagement processes and stakeholder groups inform its citizenship and sustainability approach and reporting strategy. Notably, Johnson & Johnson demonstrates excellence in reporting on sustainability context via its solutions to health issues and challenges at the global level as part of the company’s Health for Humanity theme.

BSR also recognizes that Johnson & Johnson incorporated BSR’s recommendations to more clearly identify key performance indicators for each priority issue and to categorize and organize the report’s Data Summary table by priority issue, improving the decision-usefulness of the company’s reporting.

Areas for improvement include more explicitly linking Johnson & Johnson’s sustainability strategy to the overall business strategy described in the company’s Form 10-K, being more candid in the acknowledgment of any shortcomings during the reported period, and driving further conciseness by moving certain case studies to the company’s website or in a separate report.

Assumptions and Considerations

Acquisitions

Environment, health and safety (EHS) and employee health and wellness data of newly acquired companies are integrated into the data provided in the Report three years after acquisition, unless otherwise noted. Particularly for EHS data, this grace period allows the new acquisitions to adjust their EHS management and reporting systems to Johnson & Johnson standards. The dates and details of recent acquisitions can be found in Note 20 (Business Combinations and Divestitures) on page 71 of our 2017 Annual Report.

Divestitures

Except for injury statistics and violations or fines that remain included in our Report up through the year of divestment, EHS and employee health and wellness data of divested companies are removed from the data in that year’s reporting cycle (i.e., if divested in 2017, then removed from the 2017 Report published in June 2018), unless otherwise noted.

Restatements

Should any significant changes be required in previously reported data, the data will be re-stated. For significance, we use a 5% change threshold. There are a number of potential reasons that may lead to a restatement of either prior periods or baseline data (e.g., a significant change in newly published measures, new acquisitions or divestitures, data errors, or improvements in data collection methodology over time). Depending on circumstances, each is evaluated using this threshold, and appropriate disclosures are included in the Report.

Headcount Reporting

All employee headcount data in the Report are based on data from the current Human Resources Information Systems (HRIS). Where appropriate, the Report includes a footnote to disclose the inconsistency of the HRIS headcount it presents, with the financial headcount data found in Annual Report/Form 10-K.

More Resources
You are leaving jnj.com and entering a third party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties. Continue